Burning Rock Biotech Limited (BNR.IL)
| Previous close | 7.15 |
| Open | 0.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 7.15 - 7.15 |
| 52-week range | 7.15 - 25.50 |
| Volume | |
| Avg. volume | 6 |
| Market cap | 734.126M |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.17 |
| Earnings date | 29 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireBurning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the m
- GlobeNewswire
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion dia
- Thomson Reuters StreetEvents
Q1 2024 Burning Rock Biotech Ltd Earnings Call
Q1 2024 Burning Rock Biotech Ltd Earnings Call
